Nov 9, 2021, 15:47 PM by

Rho , a full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it will be the Statistical and Clinical Coordinating Center for the COVID-19 Vaccine in Autoimmune Disease Non-Responders study. This clinical trial will assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune diseases who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune diseases improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

Nov 9, 2021, 15:47 PM by

Nov 9, 2021, 15:45 PM by

An extensive offering of liquid stable and ready-to-use combined Total Protein/Albumin clinical reference materials are now available from VERICHEM specifically designed and manufactured for the calibration and calibration verification of the analytes on a large number of clinical testing systems,

Nov 9, 2021, 15:45 PM by

Introducing BeatBox: PreOmics launches its new sample preparation tool for tissues and cells

Nov 9, 2021, 15:44 PM by

The new global Rare Disease center of Emmes expects accelerating growth from US and European biotechs

Nov 9, 2021, 15:44 PM by

The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.

Nov 9, 2021, 15:44 PM by

Innovative Wisconsin-Based Healthcare Network Deploying Kyruus ProviderMatch® Platform to Modernize How Consumers Find Providers Online

Nov 9, 2021, 15:44 PM by

2bPrecise™ announced its Precision Health™ platform is now available in the Epic App Orchard Gallery.

Nov 9, 2021, 15:44 PM by

Life Science Integrates (LSI) is delighted to announce the exciting agenda for its flagship event, Pharma Integrates, held live online on 16th November 2021.

Nov 9, 2021, 15:44 PM by

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Nov 9, 2021, 15:44 PM by

Nov 9, 2021, 15:44 PM by

Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base

Nov 9, 2021, 15:44 PM by

230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development

Nov 9, 2021, 15:44 PM by

Qlucore AB (public) (“Qlucore” or “Company”) has today received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares will be 5th November 2021. Trading will be done with the ticker QCORE.

Nov 9, 2021, 15:44 PM by

The Community Blood Center is the latest regional blood center to embrace biolog-id’s technology. Biolog-id’s solution for platelet lifecycle management will be deployed to support the efficiency of platelet manufacturing, documentation, and inventory management.

Nov 9, 2021, 15:44 PM by

Pillar VC and Petri have announced the winners of the $200K Pitch Competition that took place during the Founder-Led Biotech Summit, a free virtual event that brought together biotech founders, faculty, PhDs, scientists, investors, and executives to support the founder-led biotech movement.

Nov 9, 2021, 15:44 PM by

Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.

Nov 9, 2021, 15:44 PM by

Nov 5, 2021, 01:00 AM by User Not Found

Bio-IT World | Using genetic sequencing to identify pathogens and respond to outbreaks is hardly new. The emergence of the SARS-CoV-2 in late 2019 was a game-changer, however. While SARS-CoV-2 was identified and sequenced in record time, it proved impossible to contain. It quickly became apparent that existing surveillance systems were not up to the task of tracking a fast-moving virus that spread asymptomatically. The speed and scale of Coronavirus spread provided a wake-up call highlighting our vulnerability to a global pandemic. But bioinformatics plays a crucial role.

Nov 3, 2021, 01:00 AM by User Not Found

Bio-IT World | Researchers at the University of Buffalo (UB) have come up with a nanoparticle platform for oral prophylactic immunotherapy designed to pre-expose the immune system to medications it might otherwise perceive as foreign and attack. If translated to the clinic, their novel “reverse vaccination” approach could be used to desensitize patients to key proteins in drug treatments for rare conditions, autoimmune diseases, and allergies.